Euroscreen FAST Adds TANGO Beta-Arrestin Assay Technology to its Expanding Offer for GPCR Services

Share Article

Euroscreen SA, a global leader in the discovery of innovative drugs targeting G protein-coupled receptors (GPCRs), announced today that its business unit, Euroscreen FAST signed an agreement with Life Technologies Corporation for access to its TANGO beta-arrestin cell lines for use in drug discovery research services to be provided to Euroscreen FAST customers worldwide. Euroscreen FAST will immediately provide cell-based beta-arrestin assays as a service to customers to continue leveraging its leadership position in the GPCR custom services market. Such additional testing will extend its offer of over 700 different assays for 300 GPCRs.

Euroscreen SA, a global leader in the discovery of innovative drugs targeting G protein-coupled receptors (GPCRs), announced today that its business unit, Euroscreen FAST signed an agreement with Life Technologies Corporation for access to its TANGO beta-arrestin cell lines for use in drug discovery research services to be provided to Euroscreen FAST customers worldwide. Euroscreen FAST will immediately provide cell-based beta-arrestin assays as a service to customers to continue leveraging its leadership position in the GPCR custom services market. Such additional testing will extend its offer of over 700 different assays for 300 GPCRs.

The TANGO beta-arrestin technology is a patented, universal GPCR testing technology proven to be an accurate method for screening potential drug candidates against known and orphan GPCR targets.

The agreement provides for Euroscreen's use of Life Technologies Corporation's TANGO beta-arrestin cell lines for drug discovery research services. The parties have also agreed on terms that would allow for future development of new GPCR-based reagent assays. Financial terms of this agreement were not disclosed.

"Our primary objective is to provide our existing customers with this powerful GPCR testing technology and to expand our offer of services. We will also use this in selected research programs for deorphanization or drug discovery programs" stated Dr. Michel Detheux who heads Euroscreen FAST Business Unit for services and screening activities related to G protein coupled receptors (GPCRs).

Euroscreen FAST provides customers in academic, biotechnology and pharmaceutical research groups expertise in GPCR research that is recognized worldwide. The business unit provides scientific data and flexibility to support its customers' specific research needs. Research services encompass functional High Throughput Screening, molecular pharmacology, functional profiling, functional antibodies development and testing and custom assay development - all based upon the largest catalog of functional assays targeting GPCRs. Euroscreen FAST also provides research services for deorphanization of GPCRs by combining the largest collection of tissue extracts with different assay formats. Euroscreen FAST's growing business capitalizes on over 15 years of validation and constant improvements in GPCR assay development at Euroscreen SA.

For further information, please contact:

Euroscreen S.A.
Tel: +32 71 348 500
email: FAST(at)euroscreen(dot)com                         LicensingBD(at)euroscreen(dot)com

Michel Detheux, Ph.D.                 Al Gray, Ph.D.
Director, Euroscreen FAST Business Unit      Director, Business Development

About Euroscreen S.A.
Euroscreen, a privately held company based in Brussels, Belgium, is a preclinical-stage biopharmaceutical company focusing on the discovery, development and partnering of small molecule drugs for unmet medical needs. Euroscreen is developing a pipeline of compounds targeting G Protein-Coupled Receptors (GPCRs) using over 15 years of experience in research and commercialization of this critical class of drug targets.

Euroscreen is now in preclinical development with internal drug candidates for GPR43, a proprietary GPCR implicated in metabolic and inflammatory disorders. The Company is also advancing several other early, preclinical GPCR programs.

The Company developed a broad target portfolio for licensing to biopharmaceutical companies. Such patents address GPCRs such as CCR5, Chemerin receptor, GPR43, GPR7/8, ORL1-R, FPRL2, purinergic receptors (P2Y4, P2Y11 and P2Y13) and SHIP2 for type II diabetes. Euroscreen is able to offer intellectual property rights to companies for the development of therapeutic drugs that act through these targets.

Euroscreen pursues a dual business model combining its internal drug discovery programs with its custom screening business unit (Euroscreen FAST), to provide GPCR customized screening and other services for biotechnology and pharmaceutical companies, as well as academic researchers around the world. The company has ongoing research and licensing partnerships with AstraZeneca, Boehringer Ingelheim, BMS Company, Cephalon, Grunenthal, HGS, Monogram Biosciences, Novartis and Pfizer.
(http://www.euroscreen.com& http://www.euroscreen-fast.com)

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

ALFRED GRAY
Visit website